Effect of exogenous IL-37 on immune cells from a patient carrying a potential IL37 loss-of-function variant: A case study

•A heterozygous pLoF variant in IL37 (IL37 Chr2(GRCh37):g.113670640G > A NM_014439.3:c.51G > A p.(Trp17*)) was identified in a single patient with a seronegative autoimmune disorder. The variant does not reduce circulating IL-37 plasma concentrations, which are in fact elevated and stable over a period of six months.•T-cells appear more responsive to recombinant IL-37 compared to monocytes and neutrophils, thus IL-37 may particularly be a treatment option for immune disorders characterised by hyperresponsive T-cell subsets.